Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Study of ZE66-0205 in Healthy Volunteers
NCT07735728Phase 1Not yet recruiting
- Sponsor
- Eilean Therapeutics
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ZE66-0205 (5 arms), sponsored by Eilean Therapeutics. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of serious adverse events and 7 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ZE66-0205
Beyond the preview
Go deeper on NCT07735728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07735728.